Akzo Nobel N.v.

Akzo N.v.

Sanofi Sa

Other

Internationale Octrooi Maatschappij 'octropa' Bv

Elf Sanofi

De Staat Der Nederlanden

Snofi, S.a.

Constant A Van Boeckel

Maurice Petitou

Gijsbert W Van Dedem

Jacobus H Van Boom

Tom Beetz

Peter Hoogerhout

Eduard C Beuvery

Jan T Poolman

Peter Diederik Grootenhuis

Guy F Jaurand

Franciscus M Kaspersen

Wilhelmus H Kuijpers

Neeltje A Kraayeveld

Pieter Westerduin

Adolf Evenberg

Gijsbert A Van Den Marel

The invention relates to sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type, of which N-sulfate, N-acetate, and hydroxy groups, are replaced by alkoxy, aryloxy, aralkoxy, or O-sulfate groups. The compounds have antithrombotic and smooth muscle cell proliferation inhibiting activities.

Sulfated glycosaminoglycanoid derivatives of the heparin sulfate type

The invention relates to novel labelled modified oligonucleotides useful for anti-sense therapy, a conjugate of a targeting moiety, such as an antibody and a modified oligonucleotide complementary to the labelled oligonucleotide, the combination of both being useful in therapy of viral infections, tumours and (auto)immunodiseases. Also disclosed are pharmaceutical formulations comprising the various compounds.

Targeted delivery of a therapeutic entity using complementary

The invention relates to a tuneable bisconjugate comprising two saccharides and a spacer, each saccharide being the same or different and comprising two to six monosaccharide units, at least one unit being uronic acid, characterized in that at least one of the saccharides per se has anti-thrombotic activity, and that the spacer connects at least one saccharide to the other through its non-reducing end, the chain length of the spacer being 20-120 atoms.

Bisconjugates comprising two saccharides and a spacer

The invention relates to sulfated glycosaminoglycanoid derivatives of the dermatan sulfate and chondroitin sulfate type, of which N-sulfate, N-acetate, and hydroxy groups, are replaced by alkoxy, aryloxy, aralkoxy, or O-sulfate groups. The compounds have antithrombotic and smooth muscle cell proliferation inhibiting activities.

Sulfated glycosaminoglycanoid derivatives of the dermatan sulfate and

Sulfated glycosaminoglycanoid derivatives of the heparin and heparan

The invention relates to 3-deoxy oligosaccharides of formula I: ##STR1## in which X represents an --OSO.sub.3.sup.- radical, a radical of formula R--O, a radical of formula: ##STR2## or a radical of formula: ##STR3## Y represents a radical of formula: ##STR4## R represents an alkyl radical, R.sub.1, R.sub.3, R.sub.5, R.sub.7, R.sub.8, R.sub.10, R.sub.12 and R.sub.13 represent a hydroxyl radical, an alkoxy radical or an --OSO.sub.3.sup.- radical,

3-deoxy oligosaccharides and pharmaceutical compositions containing them

Process for splitting off .DELTA..sup.4 -unsaturated uronic acid from glycosaminoglycan, in which the glycosaminoglycan is treated with an iodine solution or with a bleaching reagent, or with a combination thereof.

Process for splitting off .DELTA..sup.4 -unsaturated uronic acid from

The invention relates to sulfated glycosaminoglycanoid derivatives of the heparin and heparin sulfate type, of which N-sulfate, N-acetate, and hydroxy groups, are replaced by alkoxy, aryloxy, aralkoxy, or O-sulfate groups. The compounds have antithrombotic and smooth muscle cell proliferation inhibiting activities.

The invention relates to sulphated K5 antigen and sulphated K5 antigen fragments containing at least 3 monosaccharide units and salts thereof, having interesting antiangiogenic and antitumor activities and a favorable ratio of the activities with respect to anticoagulant properties. In addition, the compounds can be used for the treatment of diseases caused by envelope viruses.

Sulphated K5 antigen and sulphated K5 antigen fragments

The invention relates to new oligosaccharides comprising the structure (D-ribose-D-ribitol-phosphate).sub.m, (D-ribitol-phosphate-D-ribose).sub.m or (phosphate-D-ribose-D-ribitol).sub.m, m being 2,3,4 . . . 19 or 20, to immunogens containing such oligosaccharide, to vaccines containing such immunogens and to methods for preparing such oligosaccharides, immunogens and vaccines. The vaccine is very suitable for treating infections caused by Haemophilus influenzae type b.

Oligosaccharides, immunogens and vaccines, and methods for preparing

The present invention is dealing with new pentasaccharides of the formula I: ##STR1## These pentasaccharides have anti-thrombotic activity and especially they possess potent anti-Xa activity, inactivate thrombin via HC-II, but do not inactivate thrombin via AT-III. The invention also refers to new tetrasaccharides which may be used as intermediates in the synthesis of the above pentasaccharides.

Pentasaccharides and tetrasaccharides having anti-thrombotic activity

The present invention is dealing with certain disaccharide or trisaccharide derivatives of the lipid A type, which have interesting immuno-modulating, more particularly immuno-stimulating properties.

Disaccharide and trisaccharide derivatives of the 'Lipid A' type

The invention relates to new phosphorylating agents, a process for producing said compounds and their use in a process for the phosphorylation of organic hydroxyl compounds to obtain intermediate products useful for the production of polynucleotides. The phosphorylation is achieved without side reactions at the purine- or pyrimidine bases.

Growing community of inventors

Oss, Netherlands

Constant A Van Boeckel